A mid-stage trial found adding Rezera's experimental drug ruvonoflast strengthened the anti-inflammatory effect of semaglutide, AllSci reports.
Recap by typeshit. Full story at AllSci.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
27:27
Becky Reynolds covers her three-month update on oral Wegovy, with food hauls and how she handled eating on a cruise.
More reports are surfacing of off-target effects from obesity drugs, alongside a push at HHS to move drug development faster.
Loading…